Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down while Keeping an Eye on the Enemy

Giuseppe Aprile, Francesco Giuliani, Stefania Eufemia Lutrino, Caterina Fontanella, Marta Bonotto, Karim Rihawi, Gianpiero Fasola

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The survival improvement in metastatic colorectal cancer, achieved with more intensive chemotherapy regimens, has recently led clinicians to question the optimal duration of therapies and to consider the role of maintenance. Indeed, patients whose disease is controlled after induction chemotherapy may benefit from continuing a less intensive regimen in order to reinforce the results achieved with up-front treatment. In addition, the more favorable toxicity profile of maintenance approaches would ensure a better quality of life. After discussing the rationale and the difference of pursuing a maintenance strategy with chemotherapeutic and/or biologic agents, we present significant available data from the literature and comment on the current implications and future directions of maintenance therapy. The current roles of depotentiated treatment schedules, antiangiogenic compounds, epidermal growth factor receptor inhibitors, and novel targeted therapies are also reviewed. Finally, we address elements that may foster clinical and social debate on this topic, suggesting potential aspects that need to be further investigated.

Original languageEnglish
Pages (from-to)7-15
Number of pages9
JournalClinical Colorectal Cancer
Volume15
Issue number1
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Colorectal Neoplasms
Maintenance
Therapeutics
Induction Chemotherapy
Biological Factors
Epidermal Growth Factor Receptor
Appointments and Schedules
Quality of Life
Drug Therapy
Survival

Keywords

  • Bevacizumab
  • Colorectal cancer
  • Efatutazone
  • EGFR inhibitors
  • Erlotinib
  • Maintenance
  • MGN1703
  • Treatment duration

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Maintenance Therapy in Colorectal Cancer : Moving the Artillery Down while Keeping an Eye on the Enemy. / Aprile, Giuseppe; Giuliani, Francesco; Lutrino, Stefania Eufemia; Fontanella, Caterina; Bonotto, Marta; Rihawi, Karim; Fasola, Gianpiero.

In: Clinical Colorectal Cancer, Vol. 15, No. 1, 01.03.2016, p. 7-15.

Research output: Contribution to journalArticle

Aprile, Giuseppe ; Giuliani, Francesco ; Lutrino, Stefania Eufemia ; Fontanella, Caterina ; Bonotto, Marta ; Rihawi, Karim ; Fasola, Gianpiero. / Maintenance Therapy in Colorectal Cancer : Moving the Artillery Down while Keeping an Eye on the Enemy. In: Clinical Colorectal Cancer. 2016 ; Vol. 15, No. 1. pp. 7-15.
@article{66f6f055eb43460bbb7cb14939b6dd2f,
title = "Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down while Keeping an Eye on the Enemy",
abstract = "The survival improvement in metastatic colorectal cancer, achieved with more intensive chemotherapy regimens, has recently led clinicians to question the optimal duration of therapies and to consider the role of maintenance. Indeed, patients whose disease is controlled after induction chemotherapy may benefit from continuing a less intensive regimen in order to reinforce the results achieved with up-front treatment. In addition, the more favorable toxicity profile of maintenance approaches would ensure a better quality of life. After discussing the rationale and the difference of pursuing a maintenance strategy with chemotherapeutic and/or biologic agents, we present significant available data from the literature and comment on the current implications and future directions of maintenance therapy. The current roles of depotentiated treatment schedules, antiangiogenic compounds, epidermal growth factor receptor inhibitors, and novel targeted therapies are also reviewed. Finally, we address elements that may foster clinical and social debate on this topic, suggesting potential aspects that need to be further investigated.",
keywords = "Bevacizumab, Colorectal cancer, Efatutazone, EGFR inhibitors, Erlotinib, Maintenance, MGN1703, Treatment duration",
author = "Giuseppe Aprile and Francesco Giuliani and Lutrino, {Stefania Eufemia} and Caterina Fontanella and Marta Bonotto and Karim Rihawi and Gianpiero Fasola",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.clcc.2015.08.002",
language = "English",
volume = "15",
pages = "7--15",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Maintenance Therapy in Colorectal Cancer

T2 - Moving the Artillery Down while Keeping an Eye on the Enemy

AU - Aprile, Giuseppe

AU - Giuliani, Francesco

AU - Lutrino, Stefania Eufemia

AU - Fontanella, Caterina

AU - Bonotto, Marta

AU - Rihawi, Karim

AU - Fasola, Gianpiero

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The survival improvement in metastatic colorectal cancer, achieved with more intensive chemotherapy regimens, has recently led clinicians to question the optimal duration of therapies and to consider the role of maintenance. Indeed, patients whose disease is controlled after induction chemotherapy may benefit from continuing a less intensive regimen in order to reinforce the results achieved with up-front treatment. In addition, the more favorable toxicity profile of maintenance approaches would ensure a better quality of life. After discussing the rationale and the difference of pursuing a maintenance strategy with chemotherapeutic and/or biologic agents, we present significant available data from the literature and comment on the current implications and future directions of maintenance therapy. The current roles of depotentiated treatment schedules, antiangiogenic compounds, epidermal growth factor receptor inhibitors, and novel targeted therapies are also reviewed. Finally, we address elements that may foster clinical and social debate on this topic, suggesting potential aspects that need to be further investigated.

AB - The survival improvement in metastatic colorectal cancer, achieved with more intensive chemotherapy regimens, has recently led clinicians to question the optimal duration of therapies and to consider the role of maintenance. Indeed, patients whose disease is controlled after induction chemotherapy may benefit from continuing a less intensive regimen in order to reinforce the results achieved with up-front treatment. In addition, the more favorable toxicity profile of maintenance approaches would ensure a better quality of life. After discussing the rationale and the difference of pursuing a maintenance strategy with chemotherapeutic and/or biologic agents, we present significant available data from the literature and comment on the current implications and future directions of maintenance therapy. The current roles of depotentiated treatment schedules, antiangiogenic compounds, epidermal growth factor receptor inhibitors, and novel targeted therapies are also reviewed. Finally, we address elements that may foster clinical and social debate on this topic, suggesting potential aspects that need to be further investigated.

KW - Bevacizumab

KW - Colorectal cancer

KW - Efatutazone

KW - EGFR inhibitors

KW - Erlotinib

KW - Maintenance

KW - MGN1703

KW - Treatment duration

UR - http://www.scopus.com/inward/record.url?scp=84960110381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960110381&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2015.08.002

DO - 10.1016/j.clcc.2015.08.002

M3 - Article

AN - SCOPUS:84960110381

VL - 15

SP - 7

EP - 15

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 1

ER -